Clinical Trials
6
Active:2
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:3
Drug Approvals
10
NMPA:5
TGA:5
Drug Approvals
Indacaterol Acetate and Mometasone Furoate Powder for Inhalation（I）
- Product Name
- 茚达特罗莫米松吸入粉雾剂(Ⅰ)
- Approval Number
- 国药准字HJ20210046
- Approval Date
- Jun 18, 2021
NMPA
Indacaterol Acetate and Mometasone Furoate Powder for Inhalation（Ⅲ）
- Product Name
- 茚达特罗莫米松吸入粉雾剂(Ⅲ)
- Approval Number
- 国药准字HJ20210047
- Approval Date
- Jun 18, 2021
NMPA
Indacaterol Acetate and Mometasone Furoate Powder for Inhalation（Ⅱ）
- Product Name
- 茚达特罗莫米松吸入粉雾剂(Ⅱ)
- Approval Number
- 国药准字HJ20210048
- Approval Date
- Jun 18, 2021
NMPA
Indacaterol Acetate, Glycopyrronium Bromide and Mometasone Furoate Powder for Inhalation（Ⅱ）
- Product Name
- 茚达格莫吸入粉雾剂(Ⅱ)
- Approval Number
- 国药准字HJ20210034
- Approval Date
- May 19, 2021
NMPA
Indacaterol Acetate, Glycopyrronium Bromide and Mometasone Furoate Powder for Inhalation（Ⅰ）
- Product Name
- 茚达格莫吸入粉雾剂(Ⅰ)
- Approval Number
- 国药准字HJ20210033
- Approval Date
- May 19, 2021
NMPA
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
3 (50.0%)A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients
Phase 2
Active, not recruiting
- Conditions
- Sepsis
- Interventions
- Drug: STC314 Injection/STC314 Injection Placebo
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Grand Medical Pty Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06548854
- Locations
- 🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome
Phase 1
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Drug: STC314 injection or Placebo(rate=58.3 mg/hr)Drug: STC314 injection or Placebo(rate=87.5 mg/hr)
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Grand Medical Pty Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05000671
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Wuhan Jinyintan Hospital, Wuhan, Hubei, China
🇨🇳Wuhan Union Hospital, Wuhan, Hubei, China
A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019（COVID-19）Pneumonia
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Grand Medical Pty Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04880694
- Locations
- 🇧🇪
Onze-Lieve-Vrouwziekenhuis Aalst, VZW, Aalst, Belgium
🇧🇪Universitair Ziekenhuis Brussel, Brussel, Belgium
🇧🇪Jan Yperman Ziekenhuis vzw, Ieper, Belgium
News
No news found